Mitochondrial Dysfunction in Neurofibromatosis Type 1 Tracked Over Time
A completed observational study examining how mitochondrial function changes over time in NF1 patients and whether medications or supplements they take influence that function.
Summary
Neurofibromatosis type 1 (NF1) is a common genetic disorder affecting multiple organ systems and linked to symptoms like chronic fatigue and pain. Researchers at the University of Arkansas ran a completed clinical study exploring whether mitochondria — the energy-producing structures in cells — function abnormally in NF1 patients. Using serial blood draws from both NF1 patients and healthy controls, the team tracked how mitochondrial function changed over time. The study also assessed whether existing medications or supplements could improve mitochondrial performance. Patients completed validated questionnaires measuring fatigue and pain levels alongside the biological testing. This work is significant because mitochondrial dysfunction is increasingly recognized as a driver of aging and age-related decline, and understanding its role in NF1 could open doors to targeted interventions benefiting both NF1 patients and the broader field of mitochondrial medicine.
Detailed Summary
Neurofibromatosis type 1 (NF1) is described in the source as a common genetic disease with a broad spectrum of clinical manifestations across multiple organ systems. Beyond its hallmark skin findings and tumor predisposition, NF1 patients frequently suffer from debilitating fatigue and chronic pain — symptoms that lack clear biological explanations. Emerging interest in mitochondrial dysfunction as a potential contributor motivates the study.
This completed clinical study, sponsored by the University of Arkansas, set out to characterize mitochondrial (dys)function in NF1 patients compared to people not afflicted by NF1 (control group). Blood samples were collected at multiple time points, allowing researchers to track how mitochondrial activity changes longitudinally — a meaningful advantage over one-time cross-sectional snapshots. Participants also completed the FACIT-Fatigue scale and pain assessments, linking mitochondrial metrics to subjective symptom burden.
Importantly, the study is observational in design: the listed study procedures are blood draws and questionnaires (FACIT-F and Pain Scales), not administration of experimental therapies. The stated goal of evaluating whether medications and supplements can influence mitochondrial function refers to assessing associations in participants already taking such agents, rather than a controlled therapeutic intervention.
The relevance to longevity science is indirect but real: mitochondrial dysfunction is a well-established hallmark of aging. Insights into how a genetic condition associated with possible mitochondrial dysregulation manifests in humans — and how mitochondrial measures relate to everyday medication and supplement use — could inform future strategies for preserving mitochondrial health.
Caveats include the fact that only a brief description is publicly available, limiting detailed assessment of sample size, specific analyses, and results. The observational design cannot establish causal effects of any medication or supplement, and the study's focus on a specific genetic disease means findings may not generalize immediately to aging populations without NF1.
Key Findings
- NF1 patients and non-NF1 controls were evaluated for mitochondrial function using serial blood samples over time.
- Longitudinal design allows detection of how mitochondrial function shifts, not just a single snapshot.
- Study assessed whether medications or supplements participants were taking are associated with differences in mitochondrial function (observational, not a controlled intervention).
- Patient-reported fatigue (FACIT-F) and pain scores were collected alongside biological mitochondrial measures.
- Findings could inform broader understanding of mitochondrial dysfunction as a hallmark of aging.
Methodology
This is a completed observational clinical study enrolling NF1 patients and non-NF1 controls. Per the ClinicalTrials.gov record, the listed study procedures are blood draws and the FACIT-Fatigue and Pain Scales — no experimental therapy is administered. Multiple blood draws were collected longitudinally to assess mitochondrial function over time, and any evaluation of medication or supplement effects is based on agents participants were already taking.
Study Limitations
Only a brief study description is publicly available; sample size, specific mitochondrial assays, statistical analyses, and results are unknown. The design is observational — participants were not randomized to receive medications or supplements, so causal effects on mitochondrial function cannot be inferred. The study population has a specific genetic disease (NF1), which may limit generalizability to general aging populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: